Dehydroemetine

Dehydroemetine

Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	P01AX09 (WHO)
Identifiers
IUPAC name (11bS)-2-[[(1R)-6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-4,6,7,11b-tetrahydro-1H-pyrido[2,1-a]isoquinoline
CAS Number	4914-30-1 Y
PubChem CID	21022
ChemSpider	19773 N
UNII	7S79QT1T91
KEGG	D00828 Y
ChEMBL	ChEMBL547470 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C29H38N2O4
Molar mass	478.62 g/mol
3D model (JSmol)	Interactive image
SMILES O(c1cc2c(cc1OC)[C@H](NCC2)CC\5=C(/CC)CN4[C@H](c3c(cc(OC)c(OC)c3)CC4)C/5)C
InChI InChI=1S/C29H38N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,24-25,30H,6-12,17H2,1-5H3/t24-,25+/m1/s1 N Key:XXLZPUYGHQWHRN-RPBOFIJWSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Dehydroemetine
Articles
Most recent articles on Dehydroemetine Most cited articles on Dehydroemetine Review articles on Dehydroemetine Articles on Dehydroemetine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Dehydroemetine Images of Dehydroemetine Photos of Dehydroemetine Podcasts & MP3s on Dehydroemetine Videos on Dehydroemetine
Evidence Based Medicine
Cochrane Collaboration on Dehydroemetine Bandolier on Dehydroemetine TRIP on Dehydroemetine
Clinical Trials
Ongoing Trials on Dehydroemetine at Clinical Trials.gov Trial results on Dehydroemetine Clinical Trials on Dehydroemetine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Dehydroemetine NICE Guidance on Dehydroemetine NHS PRODIGY Guidance FDA on Dehydroemetine CDC on Dehydroemetine
Books
Books on Dehydroemetine
News
Dehydroemetine in the news Be alerted to news on Dehydroemetine News trends on Dehydroemetine
Commentary
Blogs on Dehydroemetine
Definitions
Definitions of Dehydroemetine
Patient Resources / Community
Patient resources on Dehydroemetine Discussion groups on Dehydroemetine Patient Handouts on Dehydroemetine Directions to Hospitals Treating Dehydroemetine Risk calculators and risk factors for Dehydroemetine
Healthcare Provider Resources
Symptoms of Dehydroemetine Causes & Risk Factors for Dehydroemetine Diagnostic studies for Dehydroemetine Treatment of Dehydroemetine
Continuing Medical Education (CME)
CME Programs on Dehydroemetine
International
Dehydroemetine en Espanol Dehydroemetine en Francais
Business
Dehydroemetine in the Marketplace Patents on Dehydroemetine
Experimental / Informatics
List of terms related to Dehydroemetine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Dehydroemetine is a synthetically produced antiprotozoal agent similar to emetine in its anti-amoebic properties and structure (they differ only in a double bond next to the ethyl substituent), but it produces fewer side effects. In the United States, it is manufactured by Roche.

Mechanism

Its exact mechanism is not known, but in vitro it inhibits translocation.

Uses

It is distributed by the Center for Disease Control on a compassionate use basis as an investigational drug for the treatment of metronidazole-resistant amoebiasis.

Amoebic infections

Some examples of the use of dehydroemetine in the treatment of amoebic infections include:

1. In 1993, the successful treatment of cutaneous amebiasis in a 7-year old girl with dehydroemetine and metronidazole in Mexico.
2. A double-blind study of oral dehydroemetine in the treatment of amoebiasis performed at St. Mary's Hospital, Catholic Medical College, Seoul, Republic of Korea in 1973-1974 showed dehydroemetine treatment was effective. A total of 60 patients were treated, 20 with dehydroemetine, 20 with Tiberal, and 20 with metronidazole. One-fourth of the patients treated with dehydroemetine reported adverse reactions, compared to 20% with other drugs, but no patient discontinued therapy due to the reaction. In all three cases, the drug therapy resulted in clearance of the infection, defined as negative results through an O&P exam, in all but 1-2 patients.
3. A 1979 study of 27 patients treated with dehydroemetine and various other drugs suggested all drug combinations were successful at treating amoebic liver abscesses.
4. A 1986 in vitro study compared the effects of dehydroemetine, metronidazole, ornidazole, and secnidazole on Entamoeba histolytica. Metronidazole was found to be most effective, and the other three drugs were of similar effectiveness.

In other diseases

A 1980 report described the use of dehydroemetine in treatment of herpes zoster, a condition which can produce painful neurological symptoms. The study involved 40 patients, all of whom were over 60, and compared dehydroemetine treatment to another drug. The study reported patients treated with dehydroemetine experienced relief of neuralgia with no changes in cardiovascular functions. Dehydroemetine has been investigated as a treatment for Leishmania infection.